Cargando…

Optimising pharmacotherapy in older cancer patients with polypharmacy

OBJECTIVE: Polypharmacy is frequent among older cancer patients and increases the risk of potential drug‐related problems (DRPs). DRPs are associated with adverse drug events, drug‐drug interactions and hospitalisations. Since no standardised polypharmacy assessment methods for oncology patients exi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrijkorte, Elze, de Vries, Jennifer, Schaafsma, Ron, Wymenga, Machteld, Oude Munnink, Thijs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063689/
https://www.ncbi.nlm.nih.gov/pubmed/31692151
http://dx.doi.org/10.1111/ecc.13185
_version_ 1783504738227060736
author Vrijkorte, Elze
de Vries, Jennifer
Schaafsma, Ron
Wymenga, Machteld
Oude Munnink, Thijs
author_facet Vrijkorte, Elze
de Vries, Jennifer
Schaafsma, Ron
Wymenga, Machteld
Oude Munnink, Thijs
author_sort Vrijkorte, Elze
collection PubMed
description OBJECTIVE: Polypharmacy is frequent among older cancer patients and increases the risk of potential drug‐related problems (DRPs). DRPs are associated with adverse drug events, drug‐drug interactions and hospitalisations. Since no standardised polypharmacy assessment methods for oncology patients exist, we aimed to develop one that can be integrated into routine care. METHODS: Based on the Systematic Tool to Reduce Inappropriate Prescribing (STRIP), we developed OncoSTRIP, which includes a polypharmacy anamnesis, a concise geriatric assessment, a polypharmacy analysis taking life expectancy into account and an optimised treatment plan. Patients ≥65 years with ≥5 chronic drugs visiting our outpatient oncology clinic were eligible for the polypharmacy assessment. RESULTS: OncoSTRIP was integrated into routine care of our older cancer patients. In 47 of 60 patients (78%), potential DRPs (n = 101) were found. In total, 85 optimisations were recommended, with an acceptance rate of 41%. It was possible to reduce the number of potential DRPs by 41% and the number of patients with at least one potential DRP by 30%. Mean time spent per patient was 71 min. CONCLUSIONS: Polypharmacy assessment of older cancer patients identifies many pharmacotherapeutic optimisations. With OncoSTRIP, polypharmacy assessments can be integrated into routine care.
format Online
Article
Text
id pubmed-7063689
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70636892020-03-16 Optimising pharmacotherapy in older cancer patients with polypharmacy Vrijkorte, Elze de Vries, Jennifer Schaafsma, Ron Wymenga, Machteld Oude Munnink, Thijs Eur J Cancer Care (Engl) Original Articles OBJECTIVE: Polypharmacy is frequent among older cancer patients and increases the risk of potential drug‐related problems (DRPs). DRPs are associated with adverse drug events, drug‐drug interactions and hospitalisations. Since no standardised polypharmacy assessment methods for oncology patients exist, we aimed to develop one that can be integrated into routine care. METHODS: Based on the Systematic Tool to Reduce Inappropriate Prescribing (STRIP), we developed OncoSTRIP, which includes a polypharmacy anamnesis, a concise geriatric assessment, a polypharmacy analysis taking life expectancy into account and an optimised treatment plan. Patients ≥65 years with ≥5 chronic drugs visiting our outpatient oncology clinic were eligible for the polypharmacy assessment. RESULTS: OncoSTRIP was integrated into routine care of our older cancer patients. In 47 of 60 patients (78%), potential DRPs (n = 101) were found. In total, 85 optimisations were recommended, with an acceptance rate of 41%. It was possible to reduce the number of potential DRPs by 41% and the number of patients with at least one potential DRP by 30%. Mean time spent per patient was 71 min. CONCLUSIONS: Polypharmacy assessment of older cancer patients identifies many pharmacotherapeutic optimisations. With OncoSTRIP, polypharmacy assessments can be integrated into routine care. John Wiley and Sons Inc. 2019-11-06 2020-01 /pmc/articles/PMC7063689/ /pubmed/31692151 http://dx.doi.org/10.1111/ecc.13185 Text en © 2019 The Authors. European Journal of Cancer Care published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Vrijkorte, Elze
de Vries, Jennifer
Schaafsma, Ron
Wymenga, Machteld
Oude Munnink, Thijs
Optimising pharmacotherapy in older cancer patients with polypharmacy
title Optimising pharmacotherapy in older cancer patients with polypharmacy
title_full Optimising pharmacotherapy in older cancer patients with polypharmacy
title_fullStr Optimising pharmacotherapy in older cancer patients with polypharmacy
title_full_unstemmed Optimising pharmacotherapy in older cancer patients with polypharmacy
title_short Optimising pharmacotherapy in older cancer patients with polypharmacy
title_sort optimising pharmacotherapy in older cancer patients with polypharmacy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063689/
https://www.ncbi.nlm.nih.gov/pubmed/31692151
http://dx.doi.org/10.1111/ecc.13185
work_keys_str_mv AT vrijkorteelze optimisingpharmacotherapyinoldercancerpatientswithpolypharmacy
AT devriesjennifer optimisingpharmacotherapyinoldercancerpatientswithpolypharmacy
AT schaafsmaron optimisingpharmacotherapyinoldercancerpatientswithpolypharmacy
AT wymengamachteld optimisingpharmacotherapyinoldercancerpatientswithpolypharmacy
AT oudemunninkthijs optimisingpharmacotherapyinoldercancerpatientswithpolypharmacy